Please Wait
Applying Filters...
Menu
Xls

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.accesswire.com/724162/Relief-Therapeutics-Announces-Six-Month-Stability-Data-on-a-New-Formulation-of-RLF-100-Aviptadil

ACCESSWIRE
07 Nov 2022

https://www.accesswire.com/710682/Relief-Therapeutics-Announces-Promising-Initial-Stability-Data-on-a-New-Formulation-of-RLF-100R-Aviptadil

ACCESSWIRE
03 Aug 2022
Déjà vu: FDA rejects NRx filing for emergency use in COVID-19
Déjà vu: FDA rejects NRx filing for emergency use in COVID-19

02 Jul 2022

// Nick Paul Taylor FIERCEBIOTECH

https://www.fiercebiotech.com/biotech/deja-vu-fda-rejects-nrx-filing-emergency-use-covid-19

Nick Paul Taylor FIERCEBIOTECH
02 Jul 2022

https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-provides-update-on-breakthrough-therapy-designation-btd-request-for-zyesami-aviptadil-301566128.html

PRNEWSWIRE
10 Jun 2022

https://www.fiercebiotech.com/biotech/activ-nrx-tanks-peptide-fails-nih-trial-severe-covid-19-patients

N.P. Taylor FIERCEBIOTECH
27 May 2022

https://www.clinicaltrialsarena.com/news/nrx-zyesami-covid-futility/

CLINICALTRIALSARENA
27 May 2022